Status:
COMPLETED
AmplifEYE Colonoscopy vs Standard Colonoscopy
Lead Sponsor:
Queen Elizabeth Hospital, Hong Kong
Collaborating Sponsors:
Our Lady of Maryknoll Hospital
Conditions:
Colon Polyp
Adenoma Colon
Eligibility:
All Genders
50-79 years
Phase:
NA
Brief Summary
Colonoscopy screening is proven to reduce mortality rates for colorectal cancer, which relies on early detection and removal of colonic polyps. AmplifEYE is a FDA-approved device with a row of flexibl...
Detailed Description
This is a prospective, randomized controlled study. Patients admitted to Queen Elizabeth Hospital and Our Lady of Maryknoll Hospital for colonoscopy are randomly allocated 1:1 to receive either colono...
Eligibility Criteria
Inclusion
- Aged between 50 to 79 years old
- Scheduled for screening, surveillance or diagnostic colonoscopy
Exclusion
- Colonic strictures
- History of bowel surgery
- Per-rectal bleeding within six weeks
- Inflammatory bowel disease
- Pregnancy
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2018
Estimated Enrollment :
355 Patients enrolled
Trial Details
Trial ID
NCT03814369
Start Date
March 1 2017
End Date
November 30 2018
Last Update
March 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Queen Elizabeth Hospital
Hong Kong, Hong Kong